Clinical Trial Update: Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating enteral docosahexaenoic acid to prevent necrotizing enterocolitis in preterm neonates has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Necrotizing Enterocolitis

Drugs mentioned

• Docosahexaenoic acid (docosahexaenoic acid)

Snippet

Sponsor: Coordinación de Investigación en Salud, Mexico | Conditions: Necrotizing Enterocolitis | Phase 1, Phase 2 | Status: COMPLETED